A first-in-human, prospective pilot trial of umbilical cord-derived mesenchymal stem cell eye drops therapy for patients with refractory non-Sjögren's and Sjögren's syndrome dry eye disease.

Stem Cell Res Ther · 2025 · PMC12020048 · PMID 40269970

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

did not reach statistical significancep = 0.052so close (0.05 < p ≤ 0.1)

The baseline data indicated that all patients exhibited significant DED characteristics compared to healthy controls, except for the CFS scores for NSDE patients, which did not reach statistical significance ( p = 0.052) (Table 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.